Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Exhibit 99.1 Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Rec ...

Financial Performance - Collegium Pharmaceutical reported Q1 2025 net revenue of $177.8 million, representing a 23% increase year-over-year from $144.9 million in Q1 2024 [9][24] - The company generated $149.2 million from its pain portfolio, up 3% year-over-year, with all three core products showing revenue growth [10][24] - Net revenue from Jornay PM reached $28.5 million in Q1 2025, with a year-over-year prescription growth of 24% [6][9] Strategic Initiatives - The company completed an expansion of its Jornay PM field force, adding 55 new sales representatives, bringing the total to approximately 180 [3][6] - Collegium reaffirmed its full-year 2025 guidance, projecting product revenues between $735 million and $750 million [8] - The board authorized a $25 million accelerated share repurchase program to enhance shareholder value [3][10] Cash Position and Debt Management - As of the end of Q1 2025, Collegium had cash, cash equivalents, and marketable securities totaling $197.8 million, an increase from $162.8 million at the end of 2024 [3][26] - The company paid down an additional $16.1 million in debt during the quarter [3][10] Leadership and Corporate Updates - Collegium made significant additions to its leadership team and board of directors, including the appointment of new executive leaders and board members [10][10] - The company was recognized as a Top Workplace by USA TODAY and a Best Places to Work honoree by the Boston Business Journal [10][10]

Wall Street expects a year-over-year decline in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better t ...

Group 1 - Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 24th Annual Needham Healthcare Conference from April 7-10, 2025 [1] - The fireside chat is scheduled for April 8, 2025, at 9:30 a.m. ET and will be available via live webcast [1] - A replay of the webcast will be accessible on the company's website for 90 days post-presentation [1] Group 2 - Collegium is focused on becoming a leading, diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [2] - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM®, a treatment for ADHD, marking its entry into neuropsychiatry [2] - Collegium's growth strategy includes expanding its commercial portfolio with Jornay PM as the primary growth driver and managing capital deployment in a disciplined manner [2]

STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h ...

Core Points - Collegium Pharmaceutical, Inc. announced significant changes to its Board of Directors and executive leadership team as part of a new growth phase [1][2][3] Board of Directors Changes - Michael Heffernan, Founder and Chairman, and Gwen A. Melincoff, Board Member, will retire at the Annual General Meeting (AGM) on May 15, 2025 [2] - Gino Santini, the Board's Lead Independent Director, will be appointed as the new Chairman [2] - Dr. Carlos Paya has been nominated to the Board for shareholder approval at the AGM [2] Executive Leadership Appointments - David Dieter has been appointed as Executive Vice President, General Counsel [1][4] - Jane Gonnerman has been appointed as Executive Vice President, Strategy and Corporate Development [1][4] - Dean J. Patras has been appointed as Chief People Officer [1][4] Leadership Experience - Dr. Carlos Paya brings over 30 years of experience in the biopharmaceutical industry, previously serving as CEO of Immune Design Corp. and holding senior roles at Elan Pharmaceuticals and Eli Lilly [4][5] - David Dieter previously served as Vice President, Legal at Horizon Therapeutics, managing corporate and commercial legal matters [6] - Jane Gonnerman was Senior Vice President at Amgen, responsible for the rare disease portfolio and played a key role in the $28 billion sale of Horizon to Amgen [7] - Dean J. Patras held leadership roles at Amgen and Horizon, focusing on human resources integration following acquisitions [8] Company Strategy - Collegium aims to enhance its growth by focusing on its pain management portfolio and the recently acquired Jornay PM, a treatment for ADHD [4][9] - The company is committed to improving the lives of individuals with serious medical conditions through its diversified biopharmaceutical offerings [9]

Core Insights - Collegium Pharmaceutical, Inc. is presenting real-world data on its ADHD treatment Jornay PM at the NAPNAP conference, highlighting its commitment to improving patient outcomes [1][2] Company Overview - Collegium Pharmaceutical is focused on developing differentiated medicines for serious medical conditions, with Jornay PM as a key product in its portfolio [2][15] - The company aims to grow its commercial portfolio and establish a presence in neuropsychiatry through the acquisition of Jornay PM [15] Product Information - Jornay PM is a central nervous system stimulant indicated for the treatment of ADHD in patients aged six years and older [5][14] - The product is designed to help increase attention and decrease impulsiveness and hyperactivity in individuals with ADHD [14] Conference Details - The NAPNAP 46 National Conference on Pediatric Health Care is being held in Chicago from March 10-13, 2025, where Collegium will showcase two poster presentations [1][3] - The posters will cover real-world persistence and adherence, as well as utilization data for delayed-release/extended-release methylphenidate from a large US claims database [3]

Company Overview - Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company with a strong history in drug commercialization and growth [1] - The company's primary focus is on non-abusive painkillers, and it has recently expanded its portfolio to include an ADHD medication [1] Leadership and Expertise - Sunshine Kapital's Stefan, with a BA in Finance from Halmstad University and Lincolnshire & Humberside University, has twenty years of institutional experience in Research and Portfolio Management [1] - Stefan specializes in distressed situations and value opportunities and is the CIO/Founder of Sunshine Kapital, a registered investment adviser based in Miami [1]

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceu ...